Flow-independent nitric oxide parameters in asthma: a systematic review and meta-analysis by Karvonen, Tuomas & Lehtimäki, Lauri
This is the accepted manuscript of the article, which has been published in Journal of breath 
research. 2019, 13(4), 044001.  https://doi.org/10.1088/1752-7163/ab2c99 
Flow-independent nitric oxide parameters in 
asthma: a systematic review and meta-analysis 
Tuomas Karvonen1 and Lauri Lehtimäki1,2 
1 Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland 
2 Allergy Centre, Tampere University Hospital, Tampere, Finland 
Keywords: Asthma, Nitric oxide, two-compartment model, breath tests, systematic review and meta-analysis 
Email: lauri.lehtimaki@tuni.fi 
Abstract 
Introduction 
Fractional exhaled nitric oxide (FENO) has been proposed as a non-invasive marker of inflammation in 
the lungs. Measuring FENO at several flow rates enables the calculation of flow independent NO-
parameters that describe the NO-exchange dynamics of the lungs more precisely. The purpose of this 
study was to compare the NO-parameters between asthmatics and healthy subjects in a systematic review 
and meta-analysis. 
Methods 
A systematic search was performed in Ovid Medline, Web of Science, Scopus and Cochrane Library 
databases. All studies with asthmatic and healthy control groups with at least one NO-parameter 
calculated were included.  
Results 
From 1137 identified studies, 33 were included in the meta-analysis. All NO-parameters (alveolar NO 
concentration (CANO), bronchial flux of NO (JawNO), bronchial mucosal NO concentration (CawNO) and 
bronchial wall NO diffusion capacity (DawNO)) were found increased in glucocorticoid-treated and 
glucocorticoid-naïve asthma. JawNO and CANO were most notably increased in both study groups. 
Elevation of DawNO and CawNO seemed less prominent in both asthma groups.  
Discussion 
We found that all the NO-parameters are elevated in asthma as compared to healthy subjects. However, 
results were highly heterogenous and the evidence on CawNO and DawNO is still quite feeble due to only 
few studies reporting them. To gain more knowledge on the NO-parameters in asthma, non-linear 
methods and standardized study protocols should be used in future studies. 
 Introduction 
 
Nitric oxide (NO) was first discovered in the exhaled breath of humans in 1991 (Gustafsson et al 1991) 
and two years later fractional exhaled NO (FENO) levels were found to be increased in subjects with 
asthma (Alving et al 1993). Ever since, FENO-measurement has been vigorously studied as a possible 
marker of pulmonary inflammation. Today, FENO measurement is well standardized and in clinical use in 
diagnostics and management of asthma and there are systematic reviews and official guidelines on this 
topic (GINA Report 2018, National Institute for Health and Clinical Excellence 2017). The drawback of 
FENO measurement at a single flow rate is its inability to detect the source and release mechanism of NO 
from the lower respiratory tract.  
Tsoukias and George developed the two-compartment model of pulmonary NO-dynamics in 1998 
(Tsoukias and George 1998). In this model, the lungs are divided into two different regions or 
compartments: expansible alveolar region representing the alveoli and respiratory bronchioles (generation 
18 and beyond in Weibel’s lung model (Weibel E. 1963)) and rigid airway region representing the 
conducting airways (from trachea through generation 17). The alveolar region participates in gas 
exchange, whereas bronchial region in gas conduction. (George et al 2004) This mathematical model 
describes the NO exchange dynamics in the human lungs and FENO at given flow rate is determined by 
an exponential function: 
𝐹𝐸𝑁𝑂 = 𝐶𝑎𝑤𝑁𝑂 + (𝐶𝐴𝑁𝑂 − 𝐶𝑎𝑤𝑁𝑂)𝑒
−𝐷𝑎𝑤𝑁𝑂
𝑉𝑒        Eq. 1 
Where CawNO is NO concentration in the bronchial wall (ppb), CANO is NO concentration in alveolar 
region (ppb), DawNO is NO diffusion capacity of the airway wall (pl/s/ppb) and Ve is flow rate of 
exhalation (ml/s).  
Measuring FENO at several flow rates (extended FENO measurement) enables the calculation of flow 
independent NO-parameters. Several mathematical methods based on the two-compartment model’s 
equation and its approximations have been introduced for this purpose. Some of the models use both high 
and low flow rates and utilize the original non-linear equation or its modifications (Hogman et al 2002, 
Silkoff et al 2000, Eckel et al 2014) to solve all the flow independent NO-parameters (CANO, CawNO and 
DawNO), while others (Tsoukias et al 2001, Pietropaoli et al 1999) use only medium and high flow rates 
and a linear approximation of the non-linear equation. To solve CANO and JawNO, Tsoukias et al used a 
linear approximation (T&G-method):  
VNO = CANO * Ve + JawNO         Eq. 2 
where VNO is the total NO output to the exhaled breath (VNO = FENO * Ve) and JawNO is bronchial flux of 
NO from bronchial wall to luminal air (JawNO = DawNO * (CawNO - CANO)). There are also some models 
that take into account the increasing cross-sectional area of the airways towards the periphery and 
possible back diffusion of NO from conducting airways towards alveoli (so called TMAD (trumpet 
model, axial diffusion) correction) (Condorelli et al 2007). One method differs from the others by 
utilizing only one blow with dynamically changing flow rate and is able of estimating all the NO-
parameters (Tsoukias et al 1998). These methods have been previously reviewed in detail by George and 
colleagues (George et al 2004).  
Current knowledge 
Both increased and normal levels of flow independent NO-parameters have been reported in subjects with 
asthma. JawNO is found increased in most of published studies (Lehtimaki et al 2000, Kanazawa et al 
2010, Shimoda et al 2016, Keen et al 2011, Pedroletti et al 2003), but both increased (Kanazawa et al 
2010, Shimoda et al 2016) and normal (Lehtimaki et al 2000, Keen et al 2011) levels of CANO have been 
reported in subjects with asthma. DawNO and CawNO are rarely reported in the current literature and both 
increased (Pedroletti et al 2003, Kim et al 2017) and normal (Keen et al 2011, Kim et al 2017) levels are 
reported. Some studies have focused on glucocorticoid-naïve asthma while others have measured NO 
parameters in glucocorticoid-treated asthma. Although flow-independent NO parameters have been 
studied in asthma for almost two decades with several narrative reviews published (Hogman and 
Merilainen 2007, Garcia-Rio et al 2011, Hogman 2012), extended FENO-measurement in asthma still 
lacks a systematic review and meta-analysis of the key results. 
Aims of the study 
The aim of the study was to conduct a systematic review and meta-analysis to clarify the difference in 
NO-parameters between subjects with asthma and healthy population. We divided the asthmatics into two 
groups according to whether they do or do not use glucocorticoids (inhaled glucocorticoids (ICS) or oral 
glucocorticoids (OCS)), as these are known to cause a significant change in the NO-parameters (Fritscher 
et al 2009, Spears et al 2011, Van Muylem et al 2010, Leivo-Korpela et al 2011).  
 
Methods 
Protocol and registration 
This study was part of a wider project in which we are conducting systematic reviews on technical aspects 
and clinical applicability of the multiple flow rate FENO-measurement. The study protocol was included 
in the International Prospective Register of Systematic Reviews (PROSPERO, 
www.crd.york.ac.uk/prospero/) (ID = CRD42017067968). This study focuses on extended FENO-
measurement in asthma and was conducted according to the PRISMA-statement (Liberati et al 2009) 
where appropriate. 
Eligibility criteria 
All original journal articles including at least one calculated NO-parameter in both asthmatics and healthy 
controls were included. Only studies with on-line measurements and human subjects were included (e.g. 
modellings and animal studies excluded). No other criteria were set according to the type of trial, 
participants, outcomes or interventions (PICO-elements) in the search stage.  
Search strategy 
The purpose of the original search strategy was to identify all studies that reported NO-parameter(s) for 
one or more subject group. The search was performed using the following databases: Ovid Medline, 
Scopus, Web of Science and Cochrane Library. The search was executed by using the following search 
terms: 
a. “alveol* NO” or “alveol* nitric oxide” or Calv or CANO 
b. “bronchial nitric oxide” or “bronchial NO” or JawNO or CawNO or DawNO 
c. ”nitric oxide” and (exhal* or expir*)  
d.  Citing articles to the first article describing the two-compartment model (Tsoukias and 
George 1998) 
e.  (a or b) and c or d 
The search was performed based on topic (TS=topic) in Web of Science and title, abstract and keywords 
in Scopus and Cochrane Library. In Ovid Medline, advanced search was used (database: “Ovid 
MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily, Ovid MEDLINE and Versions(R)”). No language or time scale restrictions were used. The search 
was run on 25.3.2019. 
Study selection 
Before study selection, exact duplicates were excluded by using the RefWorks built-in tools and close 
duplicates were manually inspected whether they were duplicates or not. Then, the study eligibility 
assessment was performed first according to the title and abstract. If at least one of the NO-parameters or 
multiple flow rates were mentioned, or it was suspected that the full text would, full text was included in 
further eligibility assessment. More precise exclusion criteria according to the full text assessment are 
listed in the flow chart (Figure 1). Study selection process was carried out by the authors independently 
and all disagreements were resolved in consensus. 
 
Figure 1. Flow chart of the study selection. 
Data extraction 
Data extraction was performed by one researcher and the extraction was completed in duplicate after the 
first extraction. The extracted data was also checked by the other researcher independently.  
Double publication was suspected if the NO-parameters and subject numbers were the same between 
different studies from the same group or prior usage of study population was mentioned in the article. If 
the same data had been used in more than one study, only the first publication was included in the 
analysis. Same controls were allowed but the asthmatic subjects had to be different in every study group. 
If the data needed were not included in the published paper or it was in an inappropriate form for the 
meta-analysis, the corresponding author was contacted via email. If no reply was received, study was 
excluded from the meta-analysis or was included only by applicable parts. 
Data items 
The following data items were extracted from each study: 1) reference, 2) participant demographics 
(number, age, severity/type/control of asthma as described, criteria of asthma diagnosis, FEV1 % 
predicted, smoking habits, atopy/allergy as reported, use of inhaled or systemic glucocorticoids), 3) NO-
measurement (used flow rates, used mathematical method and NO-parameter values) and 4) funding and 
conflicts of interest.  
In some studies, the NO-parameters had been calculated by using multiple mathematical methods. Results 
from only one method per study were included in this meta-analysis to reduce risk of bias caused by 
usage of different methods that are known to yield varying results and to avoid overweighting of 
individual studies in the meta-analysis. If a non-linear method was used, results from that were extracted 
and used in the meta-analysis since these methods can be used to calculate all the NO-parameters. If only 
linear methods had been used, T&G was preferred since it is the most widely used method (T&G with 
TMAD-correction and Pietropaoli-method were used only if other were not presented).  
In most studies, the NO-parameters were reported in form of mean ± SD (standard deviation) or mean ± 
SEM (standard error of mean). Results reported as SEM were converted into SD by the following 
formula: 
SD = √𝑛 ∗ 𝑆𝐸𝑀       (Higgins and Green 2011) 
If the parameters were reported in another form (i.e. median and range, median and interquartile range 
(IQR) or mean and 95 % confidence interval) they were converted into the form of mean ± SD as it was 
necessary for the meta-analysis. Parameters reported in the form of median – 1st and 3rd interquartile range 
(IQR) or median and range were converted into mean ± SD according to Wan et al (Wan et al 2014). 
Results in the form of mean and its CI 95 % were manually converted into mean ± SEM if both upper and 
lower confidence intervals were within the same distance from the mean. Data conversion was based on 
the equation:  
SD = √𝑛 * (CI upper – CI lower) / 3.92     (Higgins and Green 2011) 
In some cases, mean ± SD was calculated from scratch if the authors reported only individual subjects’ 
NO-parameters. In these cases, a test of normality was deployed (Shapiro-Wilk) and normality of the 
parameters was tested. Non-normally distributed parameters were treated as other data conversions in the 
analyses. In other cases, the authors were contacted via email and asked to provide us with a suitable form 
of data to be used in the meta-analysis. Values of JawNO were converted into pl/s if they were reported in 
another form (e.g. nl/min, nl/s). As these conversions may cause bias, the meta-analysis was also 
performed without converted results by including only studies that originally reported results as mean ± 
SD or SEM and excluding those that needed to be converted.  
Risk of bias in individual studies 
As there were no randomized controlled studies, we could not conduct the risk of bias assessment as 
generally recommended for systematic reviews. The risk of bias was assessed descriptively based on 
methodological aspects of the extended FENO-measurement, smoking habits of the study subjects, basis 
of asthma diagnosis, number of subjects and conflicts of interest in a table but these had no impact on the 
final analyses.  
Risk of interstudy bias 
The risk of publication bias across studies was first assessed by estimating funnel plots’ asymmetry. As 
visual estimation of funnel plot’s symmetry may be subjective, symmetry was also estimated formally by 
performing Egger’s test. Funnel plots were drawn only for CANO and JawNO, since sample sizes of other 
parameters were too low. Heterogeneity was assessed by calculating I2-statistics. Funnel plots were drawn 
also for studies using only T&G-method to reduce the risk of bias caused by differences between 
mathematical methods in funnel plot asymmetry. 
Characteristics of the study groups 
Asthmatics 
Asthmatics were considered glucocorticoid-naïve, if at least 2/3 of the subjects in the group were not on 
oral or inhaled glucocorticoids for at least 4 weeks. Asthmatics were considered glucocorticoid-treated if 
at least 2/3 of the subjects were on regular ICS or OCS. Atopy and allergy, short description of asthma as 
reported by the study authors, smoking habits and FEV1 % predicted are reported for each group in the 
table but these had no impact on the meta-analysis. Groups with asthma exacerbations were excluded 
from the meta-analysis.   
Controls 
Both glucocorticoid-naïve and glucocorticoid-treated asthmatic groups had their own control groups from 
the respective studies. If more than one control group was present in a study, “the healthiest” was chosen 
for the meta-analysis (e.g. group without allergy or rhinitis). Otherwise the control group was expected to 
be healthy as the authors had reported.  
Summary measures and synthesis of results 
Arithmetic mean and 95 % confidence interval of NO-parameters were calculated for each study group. 
Mean difference with 95 % confidence interval between asthmatic and healthy subjects was calculated for 
each NO-parameter within each study.   
For each individual study, a raw mean difference (MD) between the NO-parameters of asthmatic and 
healthy subjects (MD = asthma - healthy) was calculated and inverse variance weighting was deployed to 
calculate the weights for individual studies. The meta-analysis was conducted by computing mean 
differences and summary estimate with a random-effects model using DerSimonian-Laird -approach. 
Random-effects model was chosen because of considerable heterogeneity between different studies and 
we assumed that the included studies represented a random sample from a larger population and there are 
multiple confounding factors among studies. Mean difference and 95 % confidence interval was 
calculated for each side effect using the random-effect model. The mean difference of NO-parameters 
compared to healthy controls was calculated separately for asthmatics on glucocorticoids (either inhaled 
or systemic) and glucocorticoid-naïve asthmatics. We decided not to calculate mean differences between 
glucocorticoid-treated and glucocorticoid-naive asthmatics, as the nature of asthma in these groups is 
probably highly different in severity and duration of the disease. 
Meta-analysis and all related statistics were calculated using R version 3.4.3 (R Core Team 2016) and R-
package Metafor (Viechtbauer 2010). Metafor-package was deployed to draw all plots present in this 
review. 
Results 
 
Study selection 
A total of 33 studies were included in the meta-analysis. Overall, 1184 studies were identified in the 
search. Duplicates were removed, and 495 studies were left for eligibility assessment by title and abstract. 
209 studies were discarded as they clearly did not meet the eligibility criteria. After this, we were left with 
286 studies for full text assessment of eligibility and a total of 231 studies were excluded in this process 
(the study selection process better described in Figure 1). The remaining studies were searched for 
asthmatic and healthy control groups and only these were used in this project. In the final phase of study 
selection, subject groups’ applicability was checked, and 22 studies were excluded (the exact causes of 
exclusions are listed in Table 1). Risk of bias was attempted to be minimized by excluding studies in 
which information on subjects’ diagnoses or medication were too indefinite. There were missing data in 8 
studies that could not be received from the study authors. 
Table 1. Reasons of exclusion based on study groups’ properties and missing data. 
Reason of 
exclusion 
Number 
of studies 
Description References 
Missing data 5 NO-parameters not reported in a suitable 
form for the meta-analysis (e.g. mean ± 
log SD, geometric mean). 
(Silkoff et al 2000, Brindicci et al 
2007b, Williamson et al 2011, 
Kobayashi et al 2011, Malinovschi 
et al 2006) 
 1 NO-parameters of age-matched control 
group not reported. 
(Gelb et al 2012) 
 1 Number of subjects not reported. (Shorter et al 2011) 
 1 Reported data form unclear. (Brindicci et al 2007a) 
Same subjects 
used earlier 
6 The same subjects had been included in 
an earlier study. 
(Leivo-Korpela et al 2011, 
Lehtimaki et al 2002, Lehtimaki et 
al 2001, Lehtimaki et al 2005, Linn 
et al 2013, Eckel et al 2015) 
Asthma 
medication not 
congruous 
 
5 Asthmatic study group could not be 
categorized into glucocorticoid-naive or 
glucocorticoid-treated according to our 
criteria. 
(Bake et al 2014, Hogman et al 
2001, Puckett et al 2010, Shin et al 
2007, Tufvesson et al 2013) 
Asthma 
diagnosis 
indistinct 
 
2 Asthma diagnosis was based on 
questionnaires on asthma and allergy 
related symptoms, asthma-like 
symptoms. 
(Rosa et al 2011, Knihtila et al 
2018) 
Control group 
indistinct 
1 Controls had airway hyperresponsiveness 
and nasal polyposis. 
(Gelb et al 2012) 
Total 22   
 Study characteristics 
Study design was cross-sectional in most cases. A few prospective cohort studies were identified but due 
to our study design we used only the first NO-measurement if FENO-measurement had been performed 
multiple times.  
Methods: A total of 16 studies with glucocorticoid-naive and 27 with glucocorticoid-treated asthma 
groups were included in the meta-analysis. The most frequently used method in calculating the 
parameters was T&G (Tsoukias & George (Tsoukias et al 2001), used in 23 studies). Other used methods 
were HMA (Högman & Meriläinen -algorithm (Hogman et al 2002), 6 studies), T&G with TMAD 
correction (TMAD: Trumpet Model of Axial Diffusion (Condorelli et al 2007), 2 studies), Silkoff (Silkoff 
et al 2000) (1 study), Eckel (Eckel et al 2014) (1 study) and Dynamic one flow -method (Tsoukias et al 
1998) (1 study). Numerous different flow rate combinations were used in the parameter calculations 
(Details in e-supplement Table 1).  
Participants: Overall, 718 glucocorticoid-naive and 1070 glucocorticoid-treated (altogether 1788) 
asthmatics were included in the studies. They were compared to 1781 and 735 healthy subjects, 
respectively. Since some studies used the same healthy control group for comparison to glucocorticoid-
treated and glucocorticoid-naïve asthmatics, the total number of healthy subjects was not the sum of these 
figures but 2409.  
Glucocorticoid-naive asthmatic group consisted mostly of newly diagnosed and mild asthma.  
Glucocorticoid-treated asthmatics were a heterogenous group of asthmatics with different disease 
severities and treatment levels. In some cases, the authors had not described the asthmatics in detail 
except for the usage of ICS or OCS. Mostly, the groups consisted wholly of glucocorticoid-using 
asthmatics. For more details, see e-supplement tables 1 and 2. 
NO-parameters in asthma 
All NO-parameters were increased in both glucocorticoid-treated and glucocorticoid-naive asthma as 
compared to respective healthy control groups. Increase was most distinct in CANO and JawNO. DawNO 
and CawNO were also increased but increase was more restrained in both asthmatic groups. Results are 
presented in the Table 2 and Figures 2-5 and e-supplement figures 3-6. Due to marked differences 
between the two asthma groups, we did not conduct comparison between glucocorticoid-treated and 
glucocorticoid-naïve asthma, as these groups were highly heterogenous.  
 
 
 
Table 2. The NO-parameters of asthmatic and healthy subjects. 
 
 
 
 
 
 
 
 
 
Study group CANO (ppb) JawNO (pl/s) CawNO (ppb) DawNO (pl/s/ppb) 
Glucocorticoid-naive asthma     
Number of studies  15 14 3 4 
Number of subjects 
(asthma/control) 
797/1865 770/1847 221/383 542/1697 
Glucocorticoid-naive asthmatics 3.58 (2.98–4.18) 2220 (1903–2538) 198 (56–340) 16.4 (10.6–22.3) 
Healthy controls 2.32 (1.94–2.70) 727 (644–811) 121 (40–202) 14.5 (6.0–23.1) 
MD* 1.19 (0.73–1.65) ‡ 
    1418 (1102–
1734) ‡ 
34 (14–54) † 2.3 (0.8–3.8) † 
I2 (Total heterogeneity) 88.73 % 78.77 % 28.24 % 43.17 % 
Glucocorticoid-treated asthma     
Number of studies  20 18 4 4 
Number of subjects 
(asthma/control) 
1025/592 765/513 89/114 89/114 
Glucocorticoid treated 
asthmatics 
4.35 (3.76–4.95) 2077 (1666–2487) 197 (134–260) 25.9 (15.0–36.9) 
Healthy controls 2.63 (2.29–2.96) 706 (615–797) 119 (74–164) 10.7 (6.3–15.1) 
MD 1.53 (1.03–2.02) ‡ 1314 (933–1695) ‡ 77 (38–116) ‡ 13.8 (5.6–22.01) † 
I2 (Total heterogeneity) 88.92 % 94.93 % 38.92 % 92.34 % 
Data presented in the form of mean (CI 95%), * MD = Mean difference, healthy controls – asthmatics, † p-value ≤ 0.05, ‡ p-value < 0.001 
Figure 2. Difference in JawNO between healthy controls and glucocorticoid-naive asthmatics.            
Figure 3. Difference in CANO between healthy controls and glucocorticoid-naive asthmatics.   
Figure 4. Difference in JawNO between healthy controls and glucocorticoid-treated asthmatics. 
Figure 5. Difference in CANO between healthy controls and glucocorticoid-treated asthmatics. 
To check for the possible confounding effect of data conversion, the meta-analysis was also performed 
after exclusion of all studies with data conversions or known non-normally distributed NO-parameters.  
After exclusion of these studies, the main results remained the same. Both CANO and JawNO were higher 
in both asthma groups as compared to healthy controls. The number of studies reporting DawNO and 
CawNO was small (2 and 3 studies) and although the results tended to be the same after exclusion of 
studies with data conversion, there was no more statistically significant difference between healthy 
controls’ and glucocorticoid-naive asthmatics’ in DawNO and CawNO. The effect of data-conversions was 
also evaluated by combining all healthy controls in single group and no significant differences were 
noticed in CANO or JawNO when no conversion was used as intercept (results not shown). 
In addition, to asses possible effect of mathematical method on results, we combined all healthy control 
groups and investigated the possible impact of estimation methods on results by setting the used method 
as a moderator and using T&G as intercept. However, we did not find statistically significant differences. 
T&G (TMAD) yielded higher estimates for JawNO, but this result should be interpreted cautiously as 
only one study had estimated JawNO using T&G (TMAD). 
Risk of bias across studies 
A strong level of heterogeneity was observed in the mean differences between healthy and asthmatic 
subjects (I2 statistics are presented in Figures 2-5 and e-supplement figures 3-6 and Table 2). Most 
heterogenous parameters in this regard were CANO and JawNO in both asthmatic groups, whereas 
distinctly least heterogenous was CawNO. DawNO was more heterogenous in glucocorticoid-treated 
asthma (92.34 %) compared to glucocorticoid-naive (43.17 %). I2 statistics was calculated for the mean 
differences with and without data conversions. The I2 values for CANO and JawNO seemed to be lower 
after exclusion of studies with data conversions, possibly indicating bias caused by the data-conversions. 
DawNO and CawNO yielded higher values of I2 in studies without data-conversions, except DawNO in 
glucocorticoid-treated asthma.  
Heterogeneity and publication bias 
Interstudy heterogeneity was further investigated by funnel plots (e-supplement figure 1). However, 
funnel plots were drawn only for CANO and JawNO, as minimum of 10 studies is recommended to be 
included in a funnel plot (Sterne et al 2011). All funnel plots were highly asymmetrical according to the 
Egger’s test of asymmetry: glucocorticoid-treated asthmatics (CANO: z = 3.28 p < 0.01; JawNO: z = 4.01, 
p < 0.001) and glucocorticoid-naive (CANO: z = 3.18, p < 0.001; JawNO: z = 4.13, p < 0.001). After 
exclusion of other mathematical methods than T&G, Egger’s test showed little less asymmetry: 
glucocorticoid-treated asthmatics (CANO: z = 2.25 p = 0.04; JawNO: z = 3.42, p < 0.01) and 
glucocorticoid-naive (CANO: z = 3.64, p < 0.01; JawNO: z = 2.22, p = 0.06) (e-supplement figure 2). 
Discussion 
Summary of evidence 
To our knowledge, this is the first systematic review and meta-analysis addressing the flow independent 
NO-parameters in asthma. This meta-analysis showed rather concurrently that CANO and JawNO are 
increased in asthma. We consider this evidence quite strong since sample size was relatively large and the 
included studies showed similar results. However, there are many confounding factors (e.g. age, atopy, 
technical aspects) that could not be taken in account in this meta-analysis. Evidence on CawNO and 
DawNO remains still quite weak as studies had rarely reported them. More knowledge should be gained on 
these parameters to draw better conclusions on their behavior in asthma and to evaluate their clinical 
significance.  
NO parameters of the gas conducting region (CawNO, DawNO, JawNO) 
CawNO describes the concentration of NO in the bronchial wall tissue. The concentration is determined by 
the balance between the production and elimination rates of NO in the bronchial wall mucosa. Production 
is thought to represent activity of nitric oxide synthases, while elimination is either diffusion of NO from 
mucosa to luminal air or blood circulation, or consumption in chemical reactions. DawNO, on the other 
hand, describes the diffusion capacity of NO between bronchial mucosa and luminal air. DawNO is 
dependent on both physical diffusivity of NO between mucosa and air, and size of the NO-producing 
surface area. DawNO may thus be increased due to physical changes in the mucosa improving the physical 
diffusivity of NO or if the surface area producing NO increases e.g. by spreading of the asthmatic 
inflammation from central airways towards peripheral airways. On the other hand, also bronchial 
obstruction may affect DawNO, as bronchial obstruction decreases not only the cross-sectional area of 
airways but also the total mucosal surface area of the airways that is in contact with luminal air. This is 
one theory to explain decreased DawNO, and thus decreased JawNO and FENO, in state of obstruction 
(Verbanck et al 2008).  
In this meta-analysis, DawNO was elevated in both glucocorticoid-naïve and glucocorticoid-treated 
asthmatics. The exact mechanism of increased DawNO in asthma is not known, but as discussed above, it 
may be related to either spreading of the NO production towards peripheral airways or to physical 
changes in mucosa improving the actual diffusivity of NO. Both these are plausible explanations, as 
DawNO has been shown to be increased also in atopy and allergic rhinitis (Makinen et al 2009, Hogman et 
al 2011) and several physical changes in the airways have been documented in asthma as a consequence 
of airway remodeling (e.g. epithelial shedding, goblet cell hyperplasia, basal membrane thickening, 
subepithelial fibrosis and smooth muscle hypertrophy) (Fehrenbach et al 2017). Interestingly 
glucocorticoid-treatment does not seem to affect DawNO (Silkoff et al 2000, Hogman and Merilainen 
2013), suggesting that what ever the mechanism behind increased DawNO in asthma is, it is not sensitive 
to glucocorticoids. 
CawNO was mildly elevated in both asthmatic groups. However, no strong conclusions should be drawn 
based on these results as the number of studies reporting CawNO was extremely low. We decided not to 
compare the two asthmatic groups as these groups had marked differences in the severity and duration of 
asthma in addition to the low number of studies reporting CawNO. In theory, the anti-inflammatory 
medication can restrain the inflammation in the bronchial wall and thus lower CawNO and JawNO, leaving 
CawNO of glucocorticoid-naïve asthmatics higher. Inhaled glucocorticoids are known to suppress the 
expression of iNOS, which is responsible for the increased levels of NO in inflammation (Korhonen et al 
2002). Meanwhile, the possible tissue changes remain despite of the anti-inflammatory medication and 
DawNO remains unchanged. Indeed, it has been shown that ICS lower CawNO but not DawNO in acute 
asthma (Silkoff et al 2000, Hogman and Merilainen 2013).  The current literature is still deficient to draw 
exact conclusions on the behavior of DawNO in asthma and glucocorticoid-treatment and more research is 
required. This meta-analysis showed a clear trend that JawNO is elevated in both glucocorticoid-treated 
and naïve asthma. The increase in JawNO is probably due to both increase of CawNO and DawNO.  
Alveolar NO (CANO) 
Alveolar NO was found to be elevated in both asthmatic groups, possibly suggesting inflammation in the 
distal lung. Inflammation in the distal lung has been demonstrated in severe asthma using tissue biopsies 
(Kraft et al 1996) and post-mortem tissues (Mauad et al 2004). CANO has been investigated as a possible 
non-invasive marker of distal lung inflammation and elevated CANO levels are noticed to be linked to 
severe, nocturnal  and symptomatic asthma in some studies (Lehtimaki et al 2002, Lehtimaki et al 2005, 
van Veen et al 2006). However, there are several different mechanisms that may cause increase in CaNO. 
In the original two-compartment model airway generations from 18 and beyond were included in the 
alveolar compartment (Tsoukias and George 1998). Thus, the small respiratory bronchioles, which are the 
transition zone of conducting airways to gas transfer zone, are included in alveolar compartment. 
Inflammatory activity in these small airways might therefore directly increase CaNO. Other possible 
mechanisms are increased back-diffusion of NO from larger conducting airways or decreased uptake of 
NO to pulmonary circulation due to impaired diffusion of NO from alveoli to pulmonary capillaries.  
In addition to possible marker of peripheral inflammation, CANO has also been suggested as a marker of 
peripheral airway obstruction as CANO has been noticed to positively correlate with obstruction 
(Kobayashi et al 2011, Fujisawa et al 2013, Barbinova et al 2013). The effect of inhaled and systemic 
glucocorticoids on CANO is not clear, as there are conflicting results. Some studies have noticed 
decreasing of CANO with systemic glucocorticoids (Silkoff et al 2000, Van Muylem et al 2010, Gelb et al 
2004). However, fine particle ICS or systemic glucocorticoids had no significant effect in reducing CANO 
in severe asthma in a randomized controlled study (Williamson et al 2013). The idea of treating severe 
asthma with systemic glucocorticoids based on elevated CANO is that ICS is not able to reach the smallest 
conducting airways.  
Axial back-diffusion of NO and TMAD 
It has been hypothesized that the conventional methods based on the two-compartment model 
overestimate alveolar NO and underestimate bronchial NO due to axial back-diffusion of NO from the 
more NO-rich conducting region into the alveolar region. The two-compartment model assumes the 
conducting region as an even, cylinder shaped tube, neglecting the increasing total cross-sectional area of 
the bronchial lumen towards peripheral airways. As the total cross-sectional area of the bronchial lumen 
increases with every new generation of bronchi, velocity of the air flow decreases simultaneously. The 
decrease in air flow velocity is believed to be significant to allow axial back-diffusion of NO from the 
bronchial region into the alveolar region in the distal lung.  
The axial back-diffusion can lead to underestimation of JawNO and DawNO as bronchial NO diffuses from 
conducting region into alveolar region (Shin and George 2002). However, obstruction is believed to 
inhibit the back-diffusion, making the underestimation of bronchial NO greater in subjects without 
obstruction (Heijkenskjold-Rentzhog et al 2014). This may also partly explain why DawNO and JawNO 
were elevated in asthma as compared to healthy subjects: the back-diffusion of NO is higher in healthy 
subjects, leading to greater underestimation of DawNO and JawNO relative to asthmatics with obstruction. 
Condorelli et al. introduced the trumpet model of axial back-diffusion (TMAD) of NO to consider the 
axial back-diffusion by applying correction factors to the NO-parameters calculated by the conventional 
two-compartment model (Condorelli et al 2007). The trumpet model assumes the conducting region as 
trumpet-shaped instead of even cylinder-shaped, taking account the increasing total cross-sectional area 
of bronchial lumen in the lung periphery. However, the TMAD-correction applies only to subjects with 
no obstruction as peripheral obstruction can reduce the axial back-diffusion, possibly causing over-
correction (Heijkenskjold-Rentzhog et al 2014). For this reason, we did not include TMAD-corrected 
results in the meta-analysis, unless it was the only method used in a study (TMAD was the only method 
in only two included studies).  
Possible clinical applications in asthma 
The NO-parameters could be used together with other methods in the diagnosis, management and 
phenotyping of asthma. They could also be utilized in the prediction and follow-up of treatment response 
to ICS. For instance, knowing the behavior of DawNO is important if one is to plan glucocorticoid 
treatment according to FENO measurement, since DawNO is elevated in asthma and glucocorticoid 
treatment seems not to greatly influence it. For this reason, the target FENO-values for treated asthmatics 
may not be entirely normal values but set to a higher level keeping in mind the elevated DawNO and hence 
elevated FENO and JawNO regardless of normalized CawNO (Hogman and Merilainen 2007). CawNO on 
the other hand would be a better indicator for success of anti-inflammatory treatment. Treatment response 
and dosing could be titrated for each individual according to decrease in CawNO. (Hogman et al 2017) 
Measurement of CANO offers interesting possibilities for research purposes and it has been investigated 
as a possible marker of distal lung inflammation and peripheral obstruction. Systemic glucocorticoids or 
other systemically administered drugs could be given according to the inflammation in the distal airways, 
indicated by CANO. However, results about correlation with disease severity and effect of systemic 
glucocorticoid treatment are still somewhat conflicting. Further research should be done using 
standardized methodology to calculate CANO and appropriate study protocols.  
Strengths and limitations 
One strength of this study was the relatively large sample size. There were 33 included studies with 
altogether 4304 subjects that provided results from many different study groups. Our search strategy was 
also rather comprehensive as its original purpose was to identify all studies using extended FENO-
measurement.  
Despite of the rather reliable results regarding CANO and JawNO in asthma, the current knowledge has 
some considerable limitations. There is a high risk of inter-study bias, as multiple potential and known 
confounding factors were identified and the results were highly heterogenous. Methodological aspects 
included different flow rates and mathematical methods, which are known to produce different results 
(Chladkova et al 2012, Karvonen et al 2017, Roy et al 2007). Also, other possible methodological issues 
may cause bias, as extended FENO-measurement lacks standardization (e.g. analyzer calibration, time of 
measurements taking account possible diurnal variation). 
One possible source of heterogeneity is the heterogeneity within the study subjects themselves since 
asthma is a heterogenous disease. In this meta-analysis, asthmatics were grouped into two groups only 
according to glucocorticoid usage. Authors had described the asthma type, severity and control on 
different basis and the diagnosis of asthma had been made in different ways. For these reasons we chose 
not to compare the two asthmatic groups by a meta-analysis, as there are expected to be too many 
confounding factors. It would have been interesting to group the asthmatics according to the inflammation 
type (e.g. eosinophilic vs non-eosinophilic or type 2 high vs low) but this was only seldom reported, and 
study groups were heterogenous regarding the inflammation type. 
Some subjects were smokers or former smokers and smoking was not always reported. This may affect 
the results since active smoking is reported to decrease FENO in asthma (Rutgers et al 1998, Verleden et 
al 1999). Some subjects may have been exposed passively to cigarette smoke and this may have affected 
the results as cigarette smoke is known to lower FENO in healthy and asthmatic subjects (Jacinto et al 
2017). Age and height are also known to influence the NO-parameters and we could not include these in 
the analyses (Hogman et al 2017). In addition, glucocorticoid treatment was dichotomized, and we could 
not take account the dose of asthma medication. Also, some studies had asthmatic subject groups that in 
which only some of the subjects used inhaled corticosteroids (in 4 glucocorticoid-naïve and 5 
glucocorticoid-treated groups some of the subjects used ICS or other asthma control medication). Some 
authors were minority shareholders and had received gifts (e.g. NO-analyzers) or grants from NO-
analyzer manufacturers but these studies seemed not to differ from studies with no reported conflicts of 
interests. 
Increased FENO-levels are associated with eosinophilic inflammation and are positively correlated with 
sputum eosinophil count (Berry et al 2005b). Eosinophilic asthma can be either TH2-cell driven allergic 
asthma or non-allergic eosinophilic asthma (Wenzel 2012). In both these phenotypes the link between 
FENO and eosinophilia are the type 2 cytokines. IL-5 is the most important cytokine leading to 
eosinophilia while IL-13 drives iNOS expression and NO synthesis in the epithelium (Chibana et al 2008, 
Brusselle et al 2013). Ideally studies on FENO should focus only on these two eosinophilic phenotypes of 
asthma, but since the subjects were mainly not phenotyped in this regard in the original studies, the 
inclusion of non-eosinophilic subjects likely decreases differences between asthmatic and healthy subjects 
in the current analysis. 
Heterogeneity and inter-study bias were also investigated by using funnel plots, which were highly 
asymmetrical. Funnel plot’s weakness is that it may give a false impression of publication bias if high 
precision studies differ from low precision studies in effect size (e.g. studies with small sample size yield 
greater mean differences). Other explanation for the asymmetry could be systematic bias derived from 
using different mathematical models, analyzers and their calibration, flow rates or different study 
populations. We further investigated the asymmetry of the funnel plots by plotting only studies using 
T&G-method, but significant asymmetry remained in the funnel plots. One possible explanation for the 
funnel plots’ asymmetry can be publication bias. Shape of glucocorticoid-naive asthmatics’ funnel plots 
could be explained with publication bias if studies with smaller differences or no differences would have 
been left unpublished. However, publication bias is only one possible explanation and true heterogeneity 
between studies could be considered a more plausible explanation (i.e. high precision studies differ from 
low precision studies in effect size). Glucocorticoid-treated asthmatics’ funnel plots seemed more 
randomly distributed and no clear pattern was observed. 
Our study design has also some limitations. Some studies had more than one asthmatic group. We 
decided to include all study groups if they consisted of different subjects. However, this caused those 
studies with more than one asthmatic group to gain more total weighting in the meta-analysis than if there 
was only one group per study. In addition, as the meta-analysis required the results as mean ± SD, we had 
to convert results reported in other forms in order to include these studies in the meta-analysis. It has been 
noticed that JawNO is often right skewed and results were sometimes reported in other form than mean ± 
SD. Optimally, the skewed NO-parameters should have been converted into e.g. geometric mean and 
logSD for the meta-analysis. However, it is not possible to convert the data into this form without the 
original data. We could have asked these data from the authors but as we noticed, response rate was 
extremely low and most studies had reported the NO-parameters as mean ± SD. This added bias, as to 
some degree non-normally distributed data was artificially made normally distributed. However, we 
decided to include these studies in the meta-analysis as distributions of biological parameters are often 
skewed to the right, especially in diseased populations. We hypothesized that excluding all non-normally 
distributed results would underestimate the differences between healthy and diseased in the meta-analysis. 
However, converting skewed distributions to normal distribution is a rather crude approximation and we 
calculated the results also without data conversions. However, this might have excluded the studies that 
reported their results in more appropriate form than the studies reporting results as mean ± SD as JawNO 
especially is noticed to be right-skewed. Ultimately conversions seemed not to have substantial impact on 
the overall results and the effect of data-conversion was tested in healthy controls with no statistically 
significant differences. Also, a minor source of error may spring out from that some studies had to be 
excluded from the meta-analysis as missing data could not be obtained from authors.  
Future research  
Future research should focus on standardization of the multiple flow NO-measurement. NO-parameters 
have in theory promising applications in asthma and other diseases, but the current literature on their 
applicability is still quite conflicting and heterogenous. In order to investigate the utility of NO-
parameters in asthma, the impact of different methodological issues on the results must be eliminated. 
Future researchers should also use the non-linear methods and report all NO-parameters to gain more 
knowledge on CawNO and DawNO.   
Conclusions  
In summary, this meta-analysis showed a significantly elevated level of all NO-parameters in both 
glucocorticoid-treated and naive asthmatics as compared to healthy subjects. Due to only few studies 
reporting CawNO or DawNO, the evidence on these NO-parameters is still quite feeble. More research 
should be put on these NO-parameters and standardization of the extended FENO-measurement if they are 
to be taken into clinical practice.  
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